A novel drug regimen tested for the first time by researchers at Fred Hutch Cancer Center has shown great promise in preventing moderate to severe cGVHD after transplant in people who received nonmyeloablative or reduced-intensity conditioning to treat a blood cancer.
David Rimm, MD, PhD, discusses pathology limitations that have been exacerbated by the current lineup of breast cancer IHC tests.
E. Gabriela Chiorean, MD, FASCO, discusses exciting targeted therapies in the GI space and topics to be discussed at the School of Gastrointestinal Oncology meeting.
Robert F. Kenedy Jr., an antivaccine advocate and President Trump’s MAHA nominee, has cleared a key hurdle to be confirmed as secretary of Health and…
The web page for the FDA Office of Minority Health and Health Equity is no more. To access this subscriber-only content please log in or…
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.
Here is a look back on all the FDA happenings from the month of January 2025.
9th Annual Blood Cover Art Contest is now open. In recognition of authors who published in Blood and images used in advancement of science, we…
Health Affairs’ Jeff Byers welcomes Kinika Young of The Leukemia & Lymphoma Society to the program to discuss a recent final rule/advisory issued by the…
